| This week's sponsor is Eli Lilly and Company. | | | AHS 2018: Lilly Showcases Leadership in Migraine and Cluster Headache
For more than 50 years, Eli Lilly and Company has been committed to addressing the ongoing treatment challenges in neurology, primary headache disorders and chronic and recurrent pain. Learn more about Lilly's leadership in the development of innovative treatments for migraine and cluster headache here. |
Today's Rundown Despite looming resistance crisis, Novartis ducks out of antibiotics research Compass Therapeutics launches with $132M to advance a clutch of antibodies Chasing GW, Zogenix scores a win in second Dravet phase 3 Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug Genmab pays Immatics $54M to form anticancer bispecific pact Virus-free CRISPR could mean faster, more precise gene editing for T-cell therapies Pfizer’s bow to Trump won’t just hit its own prices—it’ll put a chill on hikes, period Featured Story | | | Thursday, July 12, 2018 Novartis is the latest big pharma player to decide that developing new anti-infectives isn’t on its priority list. |
|
|
Top Stories Thursday, July 12, 2018 Compass Therapeutics is coming out of stealth with $132 million in series A cash, 15 prospects in preclinical development and a lead oncology asset poised to enter the clinic in 2019. Thursday, July 12, 2018 A second confirmatory phase 3 trial of Zogenix’s Dravet syndrome drug has met its primary endpoint. The efficacy hit and an unsurprising safety profile set the company up to compete with GW Pharmaceuticals in Dravet, sending Zogenix stock up 18% in premarket trading. Thursday, July 12, 2018 A new CSO isn't all Dermavant got from GlaxoSmithKline: It has picked up the rights to the British drugmaker's phase 3-ready tapinarof in a deal worth up to £250 million ($330 million). Thursday, July 12, 2018 Genmab has paid Immatics $54 million (€46 million) to enter into an anticancer bispecific antibody pact. The upfront fee and $550 million milestone commitment buy Genmab the right to work with Immatics on the development of T-cell-engaging bispecific immunotherapies in multiple indications. Thursday, July 12, 2018 A new electroporation-based CRISPR-Cas9 method eliminated viruses from the process and laid the groundwork for safer, more precise and more efficient gene editing for CAR-T cancer treatments and other cell therapies. Wednesday, July 11, 2018 With a tweet and a phone call, President Donald Trump convinced one of the giants in pharma to retreat on price increases, at least temporarily. The upshot? It’s not good news for other price-hiking drugmakers. | This week's sponsor is ExL Events. | | Can’t-miss interactive workshop at the industry's premier Safety Labeling & Packaging event!
This 3-day conference will provide attendees with the skills needed to understand how to develop & enhance an end-to-end process to ensure a compliant label for your drug packaging.
View the agenda and workshop details! Use Discount Code C1049FIERCE to save 15% |
Resources Sponsored by: Veeva See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online 2018 Latin America Healthcare Compliance Certification Program Sao Paulo, Brazil | Sep 24-27, 2018 Join 200+ Service and Support Leaders at Field Service Amelia Island this August August 27-29, 2018 | Amelia Island, FL RESI HealthTech Week September 5-7, 2018 | Boston, MA Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA 10th International Leaders in Biobanking Congress October 14-16, 2018 | Cleveland, OH BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation |
